| Identification | Back Directory | [Name]
Seclidemstat | [CAS]
1423715-37-0 | [Synonyms]
SP2577
SP-2577
SP 2577
Seclidemstat
Seclidemstat(SP-2577)
SP-2577;SP2577;SP 2577
Benzoic acid, 3-[(4-methyl-1-piperazinyl)sulfonyl]-, (2E)-2-[1-(5-chloro-2-hydroxyphenyl)ethylidene]hydrazide | [Molecular Formula]
C20H23ClN4O4S | [MDL Number]
MFCD31630770 | [MOL File]
1423715-37-0.mol | [Molecular Weight]
450.94 |
| Chemical Properties | Back Directory | [density ]
1.39±0.1 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
DMSO : 100 mg/mL (221.76 mM);Water : < 0.1 mg/mL (insoluble) | [form ]
Solid | [pka]
7.96±0.43(Predicted) | [color ]
Off-white to yellow |
| Hazard Information | Back Directory | [Uses]
Seclidemstat is a potent noncompetitive and reversible KDM1A (LSD1) inhibitor (Ki=31 nM, IC50=13 nM). Seclidemstat promotes antitumor immunity in switch/sucrose nonfermentable (SWI/SNF) complex mutated ovarian cancer, as well as inhibit virus production, viral DNA replication, and late gene expression. Seclidemstat can be used for the research of Ewing Sarcoma[1][2]. | [IC 50]
KDM1/LSD1 | [References]
[1] Dai XJ, et al. Reversible Lysine Specific Demethylase 1 (LSD1) Inhibitors: A Promising Wrench to Impair LSD1 [published correction appears in J Med Chem. 2021 May 13;64(9):6410-6411]. J Med Chem. 2021;64(5):2466-2488. DOI:10.1021/acs.jmedchem.0c02176
[2] Soldi R, et al. The novel reversible LSD1 inhibitor SP-2577 promotes anti-tumor immunity in SWItch/Sucrose-NonFermentable (SWI/SNF) complex mutated ovarian cancer. PLoS One. 2020;15(7):e0235705. Published 2020 Jul 10. DOI:10.1371/journal.pone.0235705 |
|
|